example 7 [US8664233]   Click here for help

GtoPdb Ligand ID: 8283

Compound class: Synthetic organic
Comment: This compound is a particularly preferred example in patent US8664233 [1] which covers compounds for use in treating non-solid malignant hematological tumours, in particular, B cell leukemias.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 78.96
Molecular weight 374.19
XLogP 3.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCOc1nc(nc2c1[nH]c1c2ccc(c1)c1ccncc1)N1CCNCC1
Isomeric SMILES CCOc1nc(nc2c1[nH]c1c2ccc(c1)c1ccncc1)N1CCNCC1
InChI InChI=1S/C21H22N6O/c1-2-28-20-19-18(25-21(26-20)27-11-9-23-10-12-27)16-4-3-15(13-17(16)24-19)14-5-7-22-8-6-14/h3-8,13,23-24H,2,9-12H2,1H3
InChI Key HFGHRUCCKVYFKL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The EMA granted this compound orphan drug designation in 2007, for the treatment of chronic lymphocytic leukemia (CLL).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This compound acts as an inhibitor of phosphodiesterase E4 (gene symbol PDE4B), a cyclic adenosine monophosphate (cAMP) degrading enzyme expressed in CLL cells. Enzyme inhibition causes a rise in intracellular levels of cAMP which is believed to result in cell death.